Position in STRO
as of Mar 31, 2026
· filed Apr 28, 2026
Position Value
$1,245
+$667 QoQ
Shares Held
50
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
13 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in STRO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Bogart Wealth, LLC holds $13,935,070 across 51 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
27,703 | $13,760,911 | |
| 2 | MRNA |
Moderna, Inc.
|
437 | $30,603 | |
| 3 | EXEL |
Exelixis, Inc.
|
494 | $26,878 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
46 | $13,847 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22 | $13,717 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
63 | $11,798 | |
| 7 | RPRX |
Royalty Pharma plc
|
186 | $10,429 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
123 | $9,752 |
All Filings in STRO
Export CSV
13 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,245 | 50 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $578 | 50 | Shares | Sole | 2026-01-30 | |
| 2025-09-30 | $435 | 500 | Shares | Sole | 2025-10-27 | |
| 2025-06-30 | $355 | 500 | Shares | Sole | 2025-07-30 | |
| 2025-03-31 | $325 | 500 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $920 | 500 | Shares | Sole | 2025-01-30 | |
| 2024-09-30 | $1,730 | 500 | Shares | Sole | 2024-10-23 | |
| 2024-06-30 | $1,465 | 500 | Shares | Sole | 2024-07-31 | |
| 2024-03-31 | $2,825 | 500 | Shares | Sole | 2024-04-25 | |
| 2023-12-31 | $2,145 | 500 | Shares | Sole | 2024-02-07 | |
| 2023-09-30 | $1,735 | 500 | Shares | Sole | 2023-10-30 | |
| 2023-06-30 | $2,325 | 500 | Shares | Sole | 2023-07-31 | |
| 2023-03-31 | $2,310 | 500 | Shares | Sole | 2023-04-21 | |
| No filing history on record for this holder in this stock. | ||||||